WASHINGTON: Pfizer Inc.
on Friday estimates that the Covid-19 pandemic will not be behind us up to 2024 and say a low-dose version of its vaccine for children aged 2-4 years produces a weaker immune response than expected, potentially delaying authorization .
The company said it was testing a three-dose vaccine course in all age groups under 16 years, including children aged 2-4 years.
It was previously expected from the age group this year this year, but said it did not expect delays will significantly change the plan to submit an emergency use authorization in the second quarter of 2022.
“Data illustrates the impact of the booster and that our vaccine works best as the main regimen of three Dosage, “said Chief Scientific Officer Mikael Dolsten in a conference call.
Pfizer develops a vaccine with Germany Bontech SE.
The company has developed their vaccine version that is adjusted to combat the omicron variant that spreads rapidly, even though they have not decided whether it will be needed.
They hope to start the clinical trial for the updated vaccine in January, the Pfizer executive said.
The company said it was currently expecting a vaccine to generate revenues of $ 31 billion next year.
Specific variant shots, if necessary, can increase sales in 2022.
Pfizer and Bionech test the dose of 3-microgram vaccines in 2-5 years after using a 10-microgram dose in 5-11 years and 30-0- microgram doses in everyone More than 12.
In children aged 6 to 24 months, a low-dose version of the vaccine produces an immune response that is consistent with older vaccine receivers, the company said.
If the study of three successful doses, Pfizer and Bionech hope to submit data to the regulator to support the authorization of emergency use for children six months to under five years in the first half of 2022.